公开(公告)号：AU2008292859B2

公开(公告)日：2013-09-19

申请号：AU2008292859

申请日：2008-08-29

Applicant: ACADEMIA SINICA

Inventor： CHENG YIH-SHYUN EDMOND ,  FANG JIM-MIN ,  JAN JIA-TSRONG ,  WONG CHI-HUEY ,  SHIE JIUN-JIE

IPC: C07F9/00 ,  A61K9/16 ,  A61K31/7052 ,  A61K31/7076 ,  C07C233/52 ,  C07C247/14 ,  C07H19/04

Abstract: Novel phosphonate compounds are described. The compounds have activity as neuraminidase inhibitors against wild-type and H274Y mutant of H1N1 and H5N1 viruses. The present disclosure also provides an enantioselective synthetic route to known neuraminidase inhibitors oseltamivir and the anti-flu drug Tamiflu®, as well as novel phosphonate compounds, via D-xylose. Another efficient and flexible synthesis of Tamiflu and the highly potent neuraminidase inhibitor Tamiphosphor was also achieved in 11 steps and > 20% overall yields from the readily available fermentation product (1

公开(公告)号：CA3147075A1

公开(公告)日：2012-05-10

申请号：CA3147075

申请日：2011-11-04

Applicant: ACADEMIA SINICA

Inventor： WONG CHI-HUEY ,  MA CHE ,  TSENG YUNG-CHIEH

IPC: C12N7/00 ,  C07K1/14 ,  C07K14/11 ,  C12N7/02 ,  C12N7/04 ,  C12P21/02

Abstract: Methods for production of virus particles with simplified glycosylation on structural or surface proteins are provided. When used as targets for vaccine production, the conserved nature of such sites generates vaccines that are less sensitive to viral mutations. Use of glycosylation inhibitors for production of viruses with simplified glycosylation profiles are disclosed. An exemplary disclosure of influenza viruses and methods for production of mono-glycosylated influenza virus particles is provided. Methods for production of mono-glycosylated forms of influenza A virus, NIBRG-14 (H5N1) are provided.

公开(公告)号：NZ550945A

公开(公告)日：2010-04-30

申请号：NZ55094505

申请日：2005-05-03

Applicant: ACADEMIA SINICA

Inventor： WONG CHI-HUEY ,  WU CHUNG-YI ,  JAN JIA-TSRONG

IPC: A01N47/10 ,  A61K31/27 ,  C07C261/00 ,  C07C269/00 ,  C07C271/00

Abstract: Disclosed is a compound of formula (I), or a salt thereof, wherein R5 and R11 are alkyl substituted with aryl, and wherein the rest of the substituents are as defined in the specification. Also disclosed is the use of the above compound for treating an infection with a coronavirus.

公开(公告)号：CA2756053A1

公开(公告)日：2010-01-14

申请号：CA2756053

申请日：2009-07-10

Applicant: ACADEMIA SINICA

Inventor： WONG CHI-HUEY ,  YU ALICE ,  CHANG YA-JEN ,  LIN KUN-HSIEN ,  CHENG Y S EDMOND ,  JAN JIA-TSRONG ,  LIN YI-LING ,  HUNG JUNG-TUNG

IPC: A61K39/39 ,  A61K31/70 ,  A61P31/04 ,  A61P31/16 ,  A61P35/00

Abstract: The present disclosure relates to synthetic alpha-galactosyl ceramide (.alpha.- GalCer) analogs, and their use as immunotherapies, adju-vants, and antiviral, antibacterial, and anticancer agents. In one aspect, a method of activating a cy-tokine response in a subject includes administer-ing an effective amount of a compound to a sub-ject, wherein the subject has an adaptive immune system that includes a population of cells, the population including at least one lymphocyte and at least one antigen-presenting cell, and wherein the compound is represented by the structure of formula 1 :; or a pharmaceutically acceptable salt thereof; forming a complex between the com-pound and the antigen-presenting cell, wherein the formation of the complex results in the activa-tion of a receptor on the lymphocyte; and activat-ing the lymphocyte to produce the cytokine re-sponse.

公开(公告)号：CA3034876C

公开(公告)日：2022-10-04

申请号：CA3034876

申请日：2017-08-23

Applicant: CHO PHARMA INC ,  ACADEMIA SINICA ,  LIN NAN HORNG

Inventor： LIN NAN-HORNG ,  HUANG LIN-YA ,  SHIVATARE SACHIN S ,  CHEN LI-TZU ,  WONG CHI-HUEY ,  WU CHUNG-YI ,  CHENG TING

IPC: A61K38/47 ,  C12N9/24 ,  C12P21/02

Abstract: A mutant of EndoS2 includes one or more mutations in the sequence of a wild-type EndoS2 (SEQ ID NO:1), wherein the one or more mutations are in a peptide region located within residues 133-143, residues 177-182, residues 184-189, residues 221-231, and/or residues 227-237, wherein the mutant of EndoS2 has a low hydrolyzing activity and a high transglycosylation activity, as compared to those of the wild-type EndoS2. A method for preparing an engineered glycoprotein using the mutant of EndoS2 includes coupling an activated oligosaccharide to a glycoprotein acceptor. The activated oligosaccharide is a glycan oxazoline.

公开(公告)号：BR112013011198B1

公开(公告)日：2022-03-15

申请号：BR112013011198

申请日：2011-11-04

Applicant: ACADEMIA SINICA

Inventor： MA CHE ,  WONG CHI-HUEY ,  TSENG YUNG-CHIEH

IPC: C12N15/09 ,  C12P21/06

Abstract: métodos para produção de partículas virais com glicosilação simplificada de proteínas de superfície. métodos para produção de partículas virais com glicosilação simplificada em proteínas estruturais ou de superfície são fornecidos. quando usadas como alvos para produção de vacinas, a natureza conservada de tais sítios gera vacinas que são menos sensíveis a mutações virais. é discutido o uso de inibidores de glicosilação para produção de vírus com perfis de glicosilação simplificada. são fornecidos uma descrição ilustrativa do vírus da influenza e métodos para a produção de partículas do vírus da influenza monoglicosiladas. são fornecidos métodos para a produção de formas monoglicosiladas do vírus da influenza a, nibrg-14 (h5nl).

公开(公告)号：ES2831256T3

公开(公告)日：2021-06-08

申请号：ES11838917

申请日：2011-11-04

Applicant: ACADEMIA SINICA

Inventor： WONG CHI-HUEY ,  MA CHE ,  TSENG YUNG-CHIEH

IPC: C12P21/06 ,  A61K39/145 ,  C12N7/00 ,  C12N15/09 ,  C12P21/00

Abstract: Un método para producir un virus de la gripe desglicosilado que comprende un antígeno hemaglutinina (HA) y que tiene un solo resto de GlcNAc unido a un sitio de N-glicosilación, comprendiendo el método: a) cultivar un virus de la gripe que comprende un antígeno hemaglutinina (HA) en un hospedante adecuado en presencia de una cantidad eficaz de un inhibidor de a-manosidasa I, para producir glicoproteínas Man9(GlcNAc)2, en el que el hospedante adecuado es un huevo de gallina embrionado libre de patógenos específicos (SPF); b) recuperar el virus de la gripe producido en a); c) poner en contacto el virus de la gripe recuperado en b) con una endoglicosidasa (Endo H) para producir dicho virus de la gripe desglicosilado; y d) aislar el virus de la gripe desglicosilado.

公开(公告)号：ES2784189T3

公开(公告)日：2020-09-23

申请号：ES10756977

申请日：2010-03-26

Applicant: ACADEMIA SINICA

Inventor： WONG CHI-HUEY ,  MA CHE ,  WANG CHENG-CHI ,  CHEN JUINE-RUEY

IPC: A61K39/12 ,  A61K39/145

Abstract: Una composición inmunogénica que comprende: una glicoproteína hemaglutinina (HA) del virus de la gripe parcialmente glicosilada, en donde la glicoproteína HA comprende uno o más sitios de glicosilación a los que está unido un glicano, y en donde el glicano consiste en un residuo azúcar, dos residuos azúcar o tres residuos azúcar.

公开(公告)号：HK1254775A1

公开(公告)日：2019-07-26

申请号：HK18113821

申请日：2018-10-30

Applicant: ACADEMIA SINICA

Inventor： WONG CHI-HUEY ,  WU CHUNG-YI ,  TSAI TSUNG-I

IPC: C12P20060101

公开(公告)号：AU2017315677A1

公开(公告)日：2019-04-11

申请号：AU2017315677

申请日：2017-08-23

Applicant: ACADEMIA SINICA ,  CHO PHARMA INC ,  LIN NAN HORNG

Inventor： LIN NAN-HORNG ,  HUANG LIN-YA ,  SHIVATARE SACHIN S ,  CHEN LI-TZU ,  WONG CHI-HUEY ,  WU CHUNG-YI ,  CHENG TING

IPC: A61K38/47 ,  C12N9/24 ,  C12P21/02

Abstract: A mutant of EndoS2 includes one or more mutations in the sequence of a wild-type EndoS2 (SEQ ID NO: 1), wherein the one or more mutations are in a peptide region located within residues 133-143, residues 177-182, residues 184-189, residues 221-231, and/or residues 227-237, wherein the mutant of EndoS2 has a low hydrolyzing activity and a high tranglycosylation activity, as compared to those of the wild-type EndoS2. A method for preparing an engineered glycoprotein using the mutant of EndoS2 includes coupling an activated oligosaccharide to a glycoprotein acceptor. The activated oligosaccharide is a glycan oxazoline.